217 related articles for article (PubMed ID: 16879756)
1. Estimation of dynamical model parameters taking into account undetectable marker values.
Thiébaut R; Guedj J; Jacqmin-Gadda H; Chêne G; Trimoulet P; Neau D; Commenges D
BMC Med Res Methodol; 2006 Aug; 6():38. PubMed ID: 16879756
[TBL] [Abstract][Full Text] [Related]
2. Maximum likelihood inference for left-censored HIV RNA data.
Lynn HS
Stat Med; 2001 Jan; 20(1):33-45. PubMed ID: 11135346
[TBL] [Abstract][Full Text] [Related]
3. Modelling HIV-RNA viral load in vertically infected children.
Gray L; Cortina-Borja M; Newell ML
Stat Med; 2004 Mar; 23(5):769-81. PubMed ID: 14981674
[TBL] [Abstract][Full Text] [Related]
4. Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.
Donato MF; Bastiampillai AJ; Manini M; Monico S
J Antimicrob Chemother; 2013 Apr; 68(4):974-5. PubMed ID: 23221629
[No Abstract] [Full Text] [Related]
5. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
6. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
Chary A; Winters MA; Eisen R; Knight TH; Asmuth DM; Holodniy M
J Med Virol; 2012 Mar; 84(3):431-7. PubMed ID: 22246828
[TBL] [Abstract][Full Text] [Related]
8. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
Tedder RS; Tuke P; Wallis N; Wright M; Nicholson L; Grant PR
J Viral Hepat; 2013 Jan; 20(1):65-71. PubMed ID: 23231086
[TBL] [Abstract][Full Text] [Related]
9. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling of HCV infection and treatment.
Dahari H; Shudo E; Ribeiro RM; Perelson AS
Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
[TBL] [Abstract][Full Text] [Related]
11. Analysis of left-censored longitudinal data with application to viral load in HIV infection.
Jacqmin-Gadda H; Thiébaut R; Chêne G; Commenges D
Biostatistics; 2000 Dec; 1(4):355-68. PubMed ID: 12933561
[TBL] [Abstract][Full Text] [Related]
12. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
13. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
14. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
15. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
[TBL] [Abstract][Full Text] [Related]
16. A comparative investigation of methods for longitudinal data with limits of detection through a case study.
Fu P; Hughes J; Zeng G; Hanook S; Orem J; Mwanda OW; Remick SC
Stat Methods Med Res; 2016 Feb; 25(1):153-66. PubMed ID: 22504231
[TBL] [Abstract][Full Text] [Related]
17. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood.
Müller V; Marée AF; De Boer RJ
J Virol; 2001 Mar; 75(6):2597-603. PubMed ID: 11222682
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
[TBL] [Abstract][Full Text] [Related]
19. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
